
zzso is a zzso zzso structurally and zzso similar to zzso This Phase I trial assessed the safety, zzso zzso and zzso effects of zzso at six dose levels zzso 20, 40, 60, zzso and 400 zzso The most common zzso associated with therapy included gastrointestinal zzso zzso zzso zzso flashes zzso and zzso zzso zzso Three patients with bone zzso from breast cancer developed zzso At doses greater than or equal to 40 zzso a decline in zzso and zzso occurred which was not statistically zzso At all doses tested zzso rose during zzso A dose dependent zzso blockade was seen on the zzso zzso following challenge with zzso zzso zzso zzso of zzso were reached within 4 weeks, and at doses greater than or equal to 60 zzso ranged from zzso zzso The zzso was found to be 5 days, and at three weeks following zzso of treatment zzso greater than 24 zzso were zzso The zzso and zzso zzso achieved steady state levels within 4 weeks and had zzso of 6 and 5 days zzso zzso responses were seen in 4 patients, 3 with breast cancer treated at 200 zzso and 1 with zzso cancer treated at 400 zzso 

